LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 116

Search options

  1. Article ; Online: Where Do We (INDI)GO From Here?

    Kinslow, Connor J / Brown, Paul D / Iwamoto, Fabio M / Wu, Cheng-Chia / Yu, James B / Cheng, Simon K / Wang, Tony J C

    International journal of radiation oncology, biology, physics

    2024  Volume 118, Issue 2, Page(s) 330–333

    Language English
    Publishing date 2024-01-14
    Publishing country United States
    Document type Editorial
    ZDB-ID 197614-x
    ISSN 1879-355X ; 0360-3016
    ISSN (online) 1879-355X
    ISSN 0360-3016
    DOI 10.1016/j.ijrobp.2023.09.008
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1218: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Comment: Medical therapy for recurrent or progressive meningiomas remains elusive.

    Iwamoto, Fabio M

    Neurology

    2015  Volume 84, Issue 3, Page(s) 285

    MeSH term(s) Antineoplastic Agents, Hormonal/therapeutic use ; Female ; Humans ; Male ; Meningeal Neoplasms/drug therapy ; Meningioma/drug therapy ; Neoplasm Recurrence, Local/drug therapy ; Somatostatin/analogs & derivatives
    Chemical Substances Antineoplastic Agents, Hormonal ; Somatostatin (51110-01-1)
    Language English
    Publishing date 2015-01-20
    Publishing country United States
    Document type Comment ; Journal Article
    ZDB-ID 207147-2
    ISSN 1526-632X ; 0028-3878
    ISSN (online) 1526-632X
    ISSN 0028-3878
    DOI 10.1212/WNL.0000000000001170
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui II Zs.153: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 18: Show issues
    Zs.MO 374: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: MGMT promoter methylation in 1p19q-intact gliomas.

    Kinslow, Connor / Siegelin, Markus D / Iwamoto, Fabio M / Gallitto, Matthew / Neugut, Alfred I / Yu, James B / Cheng, Simon K / Wang, Tony J C

    Research square

    2023  

    Abstract: Objective: Standard-of-care for 1p19q-intact anaplastic gliomas is defined by the international randomized phase III CATNON trial, which found an overall survival (OS) benefit for adjuvant temozolomide (TMZ) when added to radiotherapy. Paradoxically, ... ...

    Abstract Objective: Standard-of-care for 1p19q-intact anaplastic gliomas is defined by the international randomized phase III CATNON trial, which found an overall survival (OS) benefit for adjuvant temozolomide (TMZ) when added to radiotherapy. Paradoxically, TMZ did not appear to benefit patients with IDH-wildtype gliomas, regardless of
    Methods: We queried the NCDB from 2018-2019 for patients with IDH-wildtype or -mutant astrocytomas who received chemotherapy with follow-up through 2022. The Kaplan-Meier method and Cox proportional hazards regressions models were used to determine the association of
    Results: We identified 1,514 patients who were newly diagnosed with IDH-wildtype (n = 802, 33% methylated) or - mutant astrocytomas (n = 712, 48% methylated) and received chemotherapy during initial management. An unmethylated promoter was associated with poorer survival in patients with IDH-wildtype (3-year OS 34% [95%CI 29-39%] vs. 46% [95%CI 39-54%], p < .001, adjusted HR 1.53 [95%CI 1.24-1.89]) but not IDH-mutant astrocytomas (3-year OS 79% [95%CI 74-84%] vs. 80% [95%CI 75-86%], p = .81, HR 1.04 [95%CI 0.73-1.50]).
    Conclusions: This ancillary analysis supports adjuvant TMZ as standard-of-care for anaplastic astrocytomas (IDH-mutant and 1p19q-intact), irrespective of
    Language English
    Publishing date 2023-10-06
    Publishing country United States
    Document type Preprint
    DOI 10.21203/rs.3.rs-3393238/v1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: In Reply: Craniotomy and Survival for Primary Central Nervous System Lymphoma.

    Rae, Ali I / Iwamoto, Fabio M / Sonabend, Adam M

    Neurosurgery

    2018  Volume 83, Issue 4, Page(s) E192

    MeSH term(s) Central Nervous System Neoplasms/surgery ; Craniotomy ; Humans ; Lymphoma
    Language English
    Publishing date 2018-08-04
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 135446-2
    ISSN 1524-4040 ; 0148-396X
    ISSN (online) 1524-4040
    ISSN 0148-396X
    DOI 10.1093/neuros/nyy328
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1424: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 539: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: MGMT promoter methylation in 1p19q-intact gliomas.

    Kinslow, Connor J / Siegelin, Markus D / Iwamoto, Fabio M / Gallitto, Matthew / Neugut, Alfred I / Yu, James B / Cheng, Simon K / Wang, Tony J C

    Journal of neuro-oncology

    2023  Volume 166, Issue 1, Page(s) 73–78

    Abstract: Objective: Standard-of-care for 1p19q-intact anaplastic gliomas is defined by the international randomized phase III CATNON trial, which found an overall survival (OS) benefit for adjuvant temozolomide (TMZ) when added to radiotherapy. Paradoxically, ... ...

    Abstract Objective: Standard-of-care for 1p19q-intact anaplastic gliomas is defined by the international randomized phase III CATNON trial, which found an overall survival (OS) benefit for adjuvant temozolomide (TMZ) when added to radiotherapy. Paradoxically, TMZ did not appear to benefit patients with IDH-wildtype gliomas, regardless of MGMT promoter status. The authors concluded that well-powered prospective study on the clinical efficacy of TMZ for patients with IDH-wildtype anaplastic gliomas (meeting criteria for glioblastoma) is warranted. Given that the prognostic and predictive role of MGMT status for grade 2-3 gliomas is unresolved, we determined the effect of MGMT status on OS in patients with 1p19q-intact gliomas in the National Cancer Database (NCDB).
    Methods: We queried the NCDB from 2018 to 2019 for patients with diffuse (grade 2) and anaplastic (grade 3) IDH-wildtype or -mutant astrocytomas who received chemotherapy with follow-up through 2022. The Kaplan-Meier method and Cox proportional hazards regressions models were used to determine the association of MGMT with OS.
    Results: We identified 1514 patients who were newly diagnosed with IDH-wildtype (n = 802, 33% methylated) or -mutant astrocytomas (n = 712, 48% methylated) and received chemotherapy during initial management. An unmethylated promoter was associated with poorer survival in patients with IDH-wildtype (3-year OS 34% [95%CI 29-39%] vs. 46% [95%CI 39-54%], p < .001, adjusted HR 1.53 [95%CI 1.24-1.89]) but not IDH-mutant astrocytomas (3-year OS 79% [95%CI 74-84%] vs. 80% [95%CI 75-86%], p =0 .81, HR 1.04 [95%CI 0.73-1.50]).
    Conclusions: This ancillary analysis supports conclusions from the CATNON trial for adjuvant TMZ as standard-of-care for anaplastic astrocytomas (IDH-mutant and 1p19q-intact), irrespective of MGMT status. Determining the optimal strategy for diffuse gliomas that are IDH-wildtype will be particularly important. MGMT promoter methylation should be considered as a stratification factor in future clinical trials for these patients.
    MeSH term(s) Humans ; Brain Neoplasms/therapy ; Brain Neoplasms/drug therapy ; Prospective Studies ; Tumor Suppressor Proteins/genetics ; Glioma/therapy ; Glioma/drug therapy ; Glioblastoma/drug therapy ; Temozolomide/therapeutic use ; Methylation ; DNA Methylation ; DNA Repair Enzymes/genetics ; DNA Modification Methylases/genetics ; Isocitrate Dehydrogenase/genetics
    Chemical Substances Tumor Suppressor Proteins ; Temozolomide (YF1K15M17Y) ; DNA Repair Enzymes (EC 6.5.1.-) ; DNA Modification Methylases (EC 2.1.1.-) ; Isocitrate Dehydrogenase (EC 1.1.1.41) ; MGMT protein, human (EC 2.1.1.63)
    Language English
    Publishing date 2023-12-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 604875-4
    ISSN 1573-7373 ; 0167-594X
    ISSN (online) 1573-7373
    ISSN 0167-594X
    DOI 10.1007/s11060-023-04515-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1825: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Factorial clinical trials: a new approach to phase II neuro-oncology studies.

    Iwamoto, Fabio M / Lassman, Andrew B

    Neuro-oncology

    2015  Volume 17, Issue 2, Page(s) 174–176

    MeSH term(s) Antineoplastic Agents, Alkylating/therapeutic use ; Brain Neoplasms/drug therapy ; Dacarbazine/analogs & derivatives ; Female ; Glioblastoma/drug therapy ; Humans ; Isotretinoin/therapeutic use ; Male ; Pyrazoles/therapeutic use ; Sulfonamides/therapeutic use ; Thalidomide/therapeutic use
    Chemical Substances Antineoplastic Agents, Alkylating ; Pyrazoles ; Sulfonamides ; Thalidomide (4Z8R6ORS6L) ; Dacarbazine (7GR28W0FJI) ; Isotretinoin (EH28UP18IF)
    Language English
    Publishing date 2015-02
    Publishing country England
    Document type Comment ; Editorial ; Research Support, N.I.H., Extramural
    ZDB-ID 2028601-6
    ISSN 1523-5866 ; 1522-8517
    ISSN (online) 1523-5866
    ISSN 1522-8517
    DOI 10.1093/neuonc/nou314
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5307: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?

    Arrieta, Víctor A / Iwamoto, Fabio / Lukas, Rimas V / Sachdev, Sean / Rabadan, Raul / Sonabend, Adam M

    Journal of neurosurgery

    2019  Volume 132, Issue 5, Page(s) 1667–1672

    MeSH term(s) Brain Neoplasms/drug therapy ; Glioblastoma/drug therapy ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Neoadjuvant Therapy ; Patient Selection
    Chemical Substances Immune Checkpoint Inhibitors
    Language English
    Publishing date 2019-12-06
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural
    ZDB-ID 3089-2
    ISSN 1933-0693 ; 0022-3085
    ISSN (online) 1933-0693
    ISSN 0022-3085
    DOI 10.3171/2019.9.JNS192523
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uk I Zs.135: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Immunotherapy Against Gliomas: is the Breakthrough Near?

    Lukas, Rimas V / Wainwright, Derek A / Horbinski, Craig M / Iwamoto, Fabio M / Sonabend, Adam M

    Drugs

    2019  Volume 79, Issue 17, Page(s) 1839–1848

    Abstract: Immunotherapeutic approaches have been, and continue to be, aggressively investigated in the treatment of infiltrating gliomas. While the results of late-phase clinical studies have been disappointing in this disease space thus far, the success of ... ...

    Abstract Immunotherapeutic approaches have been, and continue to be, aggressively investigated in the treatment of infiltrating gliomas. While the results of late-phase clinical studies have been disappointing in this disease space thus far, the success of immunotherapies in other malignancies as well as the incremental gains in our understanding of immune-tumour interactions in gliomas has fuelled a strong continued interest of their evaluation in these tumours. We discuss a range of immunotherapeutic approaches including, but not limited to, vaccines, checkpoint inhibitors, oncolytic viruses, and gene therapies. Potential biomarkers under investigation to help elucidate which patients may respond or not respond to immunotherapeutic regimens are reviewed. Directions for future investigations are also noted.
    MeSH term(s) Glioma/immunology ; Glioma/therapy ; Humans ; Immunologic Factors/therapeutic use ; Immunotherapy
    Chemical Substances Immunologic Factors
    Language English
    Publishing date 2019-10-10
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 120316-2
    ISSN 1179-1950 ; 0012-6667
    ISSN (online) 1179-1950
    ISSN 0012-6667
    DOI 10.1007/s40265-019-01203-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 762: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma.

    Iwamoto, Fabio M / Hormigo, Adília

    Frontiers in oncology

    2014  Volume 4, Page(s) 90

    Abstract: Glioblastoma is the most common primary brain tumor in the adult and carries a poor prognosis with a median survival of only 14 months. Patients with glioblastoma are followed with MRI scans, but this technique has several limitations including low ... ...

    Abstract Glioblastoma is the most common primary brain tumor in the adult and carries a poor prognosis with a median survival of only 14 months. Patients with glioblastoma are followed with MRI scans, but this technique has several limitations including low specificity to differentiate between tumor and treatment effect. Development of serum markers could significantly improve the care of glioblastoma patients. We review the current concept of developing YKL-40 as one of the most promising serum markers for glioblastoma, the recent advances on understanding the role of YKL-40 in gliomagenesis, and the promising evidence emerging from preclinical models on using this protein as a target for anti-glioma therapy.
    Language English
    Publishing date 2014-04-28
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2649216-7
    ISSN 2234-943X
    ISSN 2234-943X
    DOI 10.3389/fonc.2014.00090
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Primary Central Nervous System Lymphoma: A Critical Review of the Role of Surgery for Resection.

    Yun, Jonathan / Iwamoto, Fabio M / Sonabend, Adam M

    Archives in cancer research

    2016  Volume 4, Issue 2

    Abstract: Background: Primary central nervous system lymphomas (PCNSL) are rare CNS tumors that carry a poor prognosis, with most patients suffering recurrence. Progress has been made in the treatment of this pathology, notably with the widespread use of systemic ...

    Abstract Background: Primary central nervous system lymphomas (PCNSL) are rare CNS tumors that carry a poor prognosis, with most patients suffering recurrence. Progress has been made in the treatment of this pathology, notably with the widespread use of systemic high dose methotrexate. However, unlike most other malignant CNS neoplasms, surgery for cytoreduction is not routinely performed for this disease, mainly as a result of negative experiences decades ago. Since these studies were published, the availability of intraoperative monitoring, MR imaging and neuro-navigation as well as surgical adjuncts such as fluorescence- guided resection have greatly improved the safety of intracranial procedures. More recent data is suggestive of a potential survival benefit for resection of single PCNSL lesions when patients are subsequently treated with modern regimen high-dose methotrexate, yet this evidence is limited, and should be interpreted conservatively.
    Methods and findings: A systematic review of the literature was performed to identify trials evaluating surgical options for the treatment of PCNSL.
    Conclusion: In this review, we provide a critical overview of the evidence favoring and discouraging resection for PCNSL. This literature suffers from several biases and limitations that must be considered in the context of the extrapolation of this literature into clinical decision-making.
    Language English
    Publishing date 2016-05-27
    Publishing country United States
    Document type Journal Article
    ISSN 2254-6081
    ISSN 2254-6081
    DOI 10.21767/2254-6081.100071
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top